Showing 121-130 of 1484 results for "".
- Topix Pharmaceuticals Rolls Out Replenix RetinolForte Treatment Serumhttps://practicaldermatology.com/news/topix-pharmaceuticals-rolls-out-replenix-retinolforte-treatment-serum/2458242/Topix Pharmaceuticals is adding Replenix® RetinolForte Treatment Serum to their portfolio of offerings. The serum’s patent-pending, time-released Micropolymer delivery system deposits retinol into t
- UofL Dermatology Chief Tapped by ACCMEhttps://practicaldermatology.com/news/uofl-dermatology-chief-tapped-by-accme/2458477/Jeffrey P. Callen, MD, chief of the Division of Dermatology at the University of Louisville School of Medicine in Kentucky, has been elected to serve on the Accreditation Review Committee (ARC) of the Accreditation Council of Continuing Medical Education (ACCME).
- Modernizing Medicine Reveals Telemedicine Component for its EMRhttps://practicaldermatology.com/news/modernizing-medicine-reveals-telemedicine-component-for-its-emr/2458890/Modernizing Medicine, Inc. revealed a new t
- EADV News: Bimekizumab Achieves High Thresholds of Clinical Response in HShttps://practicaldermatology.com/news/eadv-news-bimekizumab-achieves-high-thresholds-of-clinical-response-in-hs/2462067/UCB’s Bimekizumab treatment results in clinically meaningful improvements in Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) and the more stringent HiSCR75, HiSCR90 and HiSCR100 compared with placebo at Week 16, with improvements increasing for patients remaining in the study t
- Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201https://practicaldermatology.com/news/cabaletta-bio-receives-fda-clearance-of-ind-application-for-treatment-of-systemic-sclerosis-with-caba-201/2462036/The U.S. Food and Drug Administration (FDA) is allowing Cabaletta Bio, Inc.’s third Investigational New Drug (IND) application for CABA-201 to proceed. for a Phase 1/2 study in patients with systemic sclerosis (SSc). CABA-201 is a 4-1BB-containing fully human CD19-CAR T cell
- Timber Pharmaceuticals Announces Publication of Sub-Analysis of Phase 2b CONTROL Studyhttps://practicaldermatology.com/news/timber-pharmaceuticals-announces-publication-of-sub-analysis-of-phase-2b-control-study/2461620/Timber Pharmaceuticals announced the online publication of a sub-analysis of the Phase 2b CONTROL study, which is evaluating TMB-001, a topical isotretinoin formulated using the company’s patented IPEG delivery system, in subjects 9 years of age and older with moderate t
- NKTR-358 Demonstrates Proof of Concept in ADhttps://practicaldermatology.com/news/nktr-358-demonstrates-proof-of-concept-in-ad/2461011/Nektar Therapeutics and its partner Eli Lilly & Company’s NKTR-358 (LY3471851), a novel T regulatory (Treg) cell stimulator, demonstrated proof of concept in a Phase 1b study of patients with moderate-to-severe atopic dermatitis. The findings were presented at Eli Lilly&n
- Sasakawa Leprosy (Hansen's Disease) Launches New "Don't Forget Leprosy" Initiativehttps://practicaldermatology.com/news/sasakawa-leprosy-hansens-disease-new-initiative-dont-forget-leprosy/2460872/Sasakawa Leprosy (Hansen's Disease) Initiative is launching a campaign called "Don't Forget Leprosy" urging that activities against the disease are not sidelined amid the ongoing coronavirus pandemic. Beginning with a webinar on Aug. 4, 2021, the approximately 10-
- Cabaletta Bio Receives FDA Fast Track Designation for DSG3-CAART for the Treatment of mPVhttps://practicaldermatology.com/news/cabaletta-bio-receives-fda-fast-track-designation-for-dsg3-caart-for-the-treatment-of-mpv/2460383/The U.S. Food and Drug Administration (FDA) granted Cabaletta Bio’s DSG3-CAART (Desmoglein 3 Chimeric AutoAntibody Receptor T cells) Fast Track Designation for improving healing of mucosal blisters in patients with mPV. DSG3-CAART is designed to specifically target the cause of mP
- FDA Approves Sorilux for Adolescent Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-sorilux-for-adolescent-plaque-psoriasis/2460039/The FDA has approved Mayne Pharma Group Limited's Sorilux (calcipotriene) Foam, 0.005% in adolescents 12 years and older. The FDA approved Sorilux in 2010 based on evidence from two eight-week placebo controlled clinical trials in patients with mild to moderate plaque psoriasis of t